Neurocrine Biosciences, Inc.
NBIX
$155.80
$5.213.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 2,405.06% | 49.08% | 61.40% | 65.38% | -81.80% |
| Total Depreciation and Amortization | -3.95% | 5.63% | 18.46% | 0.00% | 22.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -177.26% | 184.21% | 25.56% | -9.00% | 209.32% |
| Change in Net Operating Assets | 87.34% | 26.41% | -4,309.09% | 54.69% | 25.00% |
| Cash from Operations | 125.00% | 60.16% | 43.99% | 57.89% | -50.27% |
| Capital Expenditure | 14.95% | 132.88% | -62.96% | -7.76% | 4.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2,350.20% | 9.34% | -659.45% | 0.60% | 156.85% |
| Cash from Investing | -3,664.79% | 22.55% | -896.36% | -2.84% | 125.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -26.48% | 273.00% | 72.73% | -8.86% | -54.08% |
| Repurchase of Common Stock | 64.00% | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 26.97% | 112.86% | 72.73% | 98.87% | -268.67% |
| Foreign Exchange rate Adjustments | -- | -- | -166.67% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,047.81% | 421.10% | -63.61% | 127.24% | -126.79% |